733 A phase 2 study of vudalimab (XmAb®20717), an anti-PD-1/CTLA-4 bispecific antibody, in patients with selected gynecological malignancies and high-risk metastatic castration-resistant prostate-cancer

Hou, J., Goodman, O., Berz, D., Yao, L., & Soni, N. (2022). 733 A phase 2 study of vudalimab (XmAb®20717), an anti-PD-1/CTLA-4 bispecific antibody, in patients with selected gynecological malignancies and high-risk metastatic castration-resistant prostate-cancer. Regular and Young Investigator Award Abstracts, A765–A765. https://doi.org/10.1136/jitc-2022-sitc2022.0733
Authors:
June Y. Hou
Oscar Goodman
David Berz
Li Yao
Nital Soni
Affiliated Authors:
June Y. Hou
Subjects:
Cancer Immunotherapy (OpenAlex Topic)
Advancements in Prostate Cancer Research (OpenAlex Topic)
Renal Cell Carcinoma (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1136/jitc-2022-sitc2022.0733
DOI:
10.1136/jitc-2022-sitc2022.0733
Journal:
Journal for ImmunoTherapy of Cancer
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: